| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.019 | 0.8 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.8 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |